TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9469674
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration when ANC < 1000/mm3 (delayed arm)
Study: 1675576
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (A50)
Study: 327585
Drug: aspirin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (4 500 mg daily)
Study: 27132052
Drug: Hysteroscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopy with treatment of detected intracavitary abnormalities before starting IVF (n=373)
Study: 27132052
Drug: Immediate start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate start of IVF treatment (n=377)
Study: 24379449
Drug: Nonmassage sham
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmassage sham treatment
Study: 23147978
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (MT)
Study: 21940484
Drug: G200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: G200 (200 mg/dL)
Study: 21940484
Drug: G100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: G100 (100 mg/dL)
Study: 15885046
Drug: Pramipexole 0.18-0.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.18-0.36 mg
Study: 16841622
Drug: Modafinil 300
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 300 mg once daily
Study: 16841622
Drug: Modafinil 200/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200/100 mg
Study: 10370786
Drug: Normal serum
Normalized name: Albumin, Normal Serum, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal serum IL-10 levels (below 10 pg/ml)
Study: 6302612
Drug: Cefuroxime (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (three times daily for 5 days)
Study: 20219000
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% (Group L, n = 15)
Study: 20219000
Drug: Levobupivacaine 0.5%
Normalized name: levobupivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.5% (Group L)
Study: 27925214
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of reboxetine (RBX) 8 mg/day with anodal tDCS
Study: 27925214
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of reboxetine (RBX) 8 mg/day with cathodal tDCS
Study: 27925214
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of reboxetine (RBX) 8 mg with anodal tDCS
Study: 27925214
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of reboxetine (RBX) 8 mg with cathodal tDCS
Study: 25964261
Drug: Automated Self‐Administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated Self‐Administered 24‐Hour Recall (ASA24)
Study: 25964261
Drug: Interviewer‐administered, Automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer‐administered, Automated Multiple‐Pass Method (AMPM)
Study: 21704241
Drug: 105-mg fenofibric
Normalized name: fenofibric acid 105 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105-mg fenofibric acid (fasted)
Study: 21704241
Drug: 145-mg fenofibrate
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145-mg fenofibrate (fasted)
Study: 21704241
Drug: 105-mg fenofibric
Normalized name: fenofibric acid 105 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105-mg fenofibric acid (fed)
Study: 21704241
Drug: 145-mg fenofibrate
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 145-mg fenofibrate (fed)
Study: 7573783
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg alcohol
Study: 31039759
Drug: Ethenox (ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethenox (ethanol 40% v/v-enoxaparin 1000 U/mL)
Study: 31039759
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) or citrate 4% w/v
Study: 23597063
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of oral disease (dental, periodontal, mucosal, and salivary) by dental surgeons trained in periodontology at baseline.
Study: 23597063
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires evaluating oral hygiene habits and thirst.
Study: 23597063
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection on hospitalizations and mortality (total and cause-specific) according to baseline oral health status.
Study: 19156086
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg per day
Study: 11138916
Drug: One gram
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One gram azithromycin monthly
Study: 3087620
Drug: 250‐mg phenoxymethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250‐mg phenoxymethyl penicillin taken orally twice daily for one to three years
Study: 3087620
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally twice daily for one to three years
Study: 30206744
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention program including usual care, multidimensional screening, verbal counselling, written instructions, home-based high-intensity functional exercise program (HIFE), and support related to cognition, mood, risk of falling, medication, nutrition and self-care.
Study: 28403961
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg per day orally for 7 days starting from hCG administration)
Study: 25920921
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum phosphorus (>5.2 mg/dL)
Study: 25920921
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum phosphorus (<3.6 mg/dL)
Study: 25920921
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum calcium (>9.5 mg/dL)
Study: 25920921
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum calcium (<7.9 mg/dL)
Study: 25920921
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum PTH (<168 pg/mL)
Study: 25920921
Drug: Serum phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum phosphorus at 4.4 mg/dL, calcium at 8.8 mg/dL, PTH at 398 pg/mL
Study: 23142957
Drug: MDMA single
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA single dose (100 mg)
Study: 15384954
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with repaglinide plus metformin
Study: 15384954
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with repaglinide
Study: 14764127
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg twice daily
Study: 9876226
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid spray (fluticasone propionate)
Study: 820365
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nitrogen treatment for hand warts
Study: 30350844
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + aspirin
Study: 24154647
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement drinks provided three times on intervention day, each drink providing 283.3+/‐41.8 Kcal and 13.8+/‐4.7g of protein
Study: 24154647
Drug: Control day
Normalized name: Avobenzone 30 mg in 1 mL / Octinoxate 75 mg in 1 mL TOPICAL LOTION [Oil-Control Day SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control day (no nutritional supplement drinks)
Study: 18326606
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HP: 2 g x kg(‐1) x d(‐1))
Study: 18326606
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (NP: 1 g x kg(‐1) x d(‐1))
Study: 16543072
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg on day 1 posttransplant
Study: 8198813
Drug: Nerisona ointment
Normalized name: Nerisone
DrugBank: Difluocortolone (DB09095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerisona ointment (DFV)
Study: 8198813
Drug: Nerisalic ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerisalic ointment (DFV + salicylic acid)
Study: 30516501
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy and Cytoflavin in addition to standard treatment
Study: 30516501
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (non-steroidal anti-inflammatory drugs, myorelaxants, chondroprotectors, physiotherapy)
Study: 24844921
Drug: Placebo phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo phototherapy device, 12 treatments
Study: 24821009
Drug: Biweekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly regimen of gemcitabine (1,000 mg/m² on days 1 and 14) and carboplatin (AUC = 3 on days 1 and 14) every 28 days
Study: 24821009
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of gemcitabine (1,000 mg/m² on days 1 and 8) and carboplatin (AUC = 5 on day 1) every 21 days
Study: 21058850
Drug: Stress Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Management Training (SMT) based on acceptance and commitment therapy, n = 177
Study: 8633511
Drug: L-365,260
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260
Study: 26548425
Drug: Anthocyanins (AC)‐rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (AC)‐rich extract from red oranges, 200 mg administered in two doses (12 and 4 hours before diving)
Study: 15929034
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate alone
Study: 15929034
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate with deferred radiotherapy
Study: 3295501
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate
Study: 9988142
Drug: RenaGel with
Normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RenaGel with calcium (900 mg elemental, once-nightly on an empty stomach)
Study: 7786885
Drug: Apomorphine HCl
Normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine HCl (0.5 mg sc)
Study: 2151747
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg BY 1023/SK&F 96022
Study: 26776270
Drug: Local RUTF
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local RUTF (alternative formulations using local ingredients)
Study: 3518407
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg, tid orally for 1 week
Study: 22430025
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection (4 mL of 0.5% bupivacaine and 40 mg methylprednisone)
Study: 22430025
Drug: Fluoroscopic-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopic-guided injection (4 mL of 0.5% bupivacaine and 40 mg methylprednisone)
Study: 22430025
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection and Fluoroscopic-guided injection
Study: 17765245
Drug: Gliclazide 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80 mg
Study: 16645536
Drug: Topical micellar
Normalized name: Douxo Micellar Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical micellar nanoparticle estradiol emulsion (MNPEE; 3.45 g daily dose containing 8.6 mg estradiol)
Study: 3276451
Drug: Intravenous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ranitidine
Study: 8529985
Drug: DMSO gel
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO gel 25%
Study: 8529985
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel base
Study: 7020816
Drug: Clomipramine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (in doses recommended for use in general practice)
Study: 20852182
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) for 3-15 days (T1)
Study: 20852182
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) scheduled (T0)
Study: 12384802
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E greater than 13 mg/day
Study: 9771181
Drug: Propofol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (up to 2.5 mg.kg‐1)
Study: 9771181
Drug: Etomidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.3 mg.kg‐1)
Study: 26936608
Drug: Uncapped chemotherapy
Normalized name: silica, trimethylsilyl capped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncapped chemotherapy in obese patients
Study: 26936608
Drug: Uncapped chemotherapy
Normalized name: silica, trimethylsilyl capped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncapped chemotherapy in overweight or normal bodyweight patients
Study: 24010867
Drug: Corrective Babbling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrective Babbling therapy
Study: 19957195
Drug: PPI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI and rebamipide therapy
Study: 2484393
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar looking pills and capsules without active components)
Study: 28910237
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg, subcutaneous injections, once weekly)
Study: 28910237
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, once weekly)
Study: 15112270
Drug: EBV CTL
Normalized name: EBV-CTL
DrugBank: Tabelecleucel (DB17072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV CTL infusion (5.0 x 10(6) EBV CTL/kg per dose, 3 infusions)
Study: 26281825
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for painful bone metastases
Study: 23006823
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fluoride treatment)
Study: 21419321
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of selenium as glycinate for 6 weeks
Study: 6336863
Drug: Metronidazole (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (oral or intravenous)
Study: 6336863
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole administered 1 hour before and at 8 and 16 hours after the operation
Study: 6336863
Drug: Erythromycin and
Normalized name: Erythromycin and zinc only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin and neomycin as preoperative bowel preparations
Study: 31778194
Drug: Hyperimmune anti-influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune anti-influenza plasma treatment in the FluPlasma trial
Study: 31778194
Drug: Self-administered live-attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered live-attenuated influenza vaccine in the SNIF trial
Study: 31778194
Drug: Three types
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three types of licensed vaccines in the PAIVED study
Study: 27165651
Drug: School-based violence
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based violence prevention programme involving teacher training in classroom behaviour management and strategies to promote children's social-emotional competence, delivered through five full-day workshops, monthly in-class coaching over 2 school terms, and weekly text messages.
Study: 22317852
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose prednisone (1 mg × kg × day for 4 weeks, then reduced to 5mg every 2 weeks up to 10mg) combined with cyclophosphamide (monthly for 6 months, then twice-monthly for 6 months)
Study: 22317852
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisone (10mg daily) combined with cyclophosphamide (ev)
Study: 22317852
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (low dose and high dose)
Study: 20196964
Drug: 6.6 g
Normalized name: FERROUS SULFATE 76.6 g in 454 g TOPICAL POWDER [Hemostat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.6 g PUFA/day
Study: 20196964
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g PUFA/day
Study: 69596
Drug: organo-heparinoid ointment
Normalized name: heparinoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: organo-heparinoid ointment (Hirudoid 40,000)
Study: 8029513
Drug: placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ointment
Study: 23838148
Drug: Repeated intravenous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intravenous infusion of astragalosides injection (AI)
Study: 23838148
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events after administration of AI
Study: 16544086
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) applied to the submental muscles for ten 1‐h treatments over two weeks.
Study: 16544086
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (A condition) during the control phase.
Study: 11938810
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of ligustrazine
Study: 11938810
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg of ligustrazine
Study: 1514168
Drug: GR32191 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 (40 mg) + heparin (5,000 IU bolus + 1,000 IU/h for 3 h)
Study: 1514168
Drug: GR32191 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 (40 mg) + placebo
Study: 1514168
Drug: GR32191 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 (80 mg) + placebo
Study: 1514168
Drug: heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin + placebo
Study: 6098035
Drug: Penicillin-sulbactam regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin-sulbactam regimen (aqueous procaine penicillin G, sulbactam, and probenecid)
Study: 18379485
Drug: Bitemporal transcranial
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitemporal transcranial magnetic therapy
Study: 16251627
Drug: Serum ferritin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ferritin concentrations > 160 microg/L in women
Study: 8891015
Drug: UVB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB therapy
Study: 12040250
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitor (ACE‐I)
Study: 17190733
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor antagonist (ARB)
Study: 31164368
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional or sensor-augmented pump therapy)
Study: 10770448
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day)
Study: 15067257
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment need assessed by the aesthetic component (AC) of the index of orthodontic treatment need (IOTN)
Study: 15067257
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment need assessed by the dental health component (DHC) of the index of orthodontic treatment need (IOTN)
Study: 15067257
Drug: Subjective need
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjective need for orthodontic treatment as assessed by a prestructured questionnaire